Adoptive cell therapy (ACT) targeting tumor-specific antigens holds promise for solid-tumors, but limited neoantigen presentation remains a key barrier to efficacy. Here, we identify and characterize a T-cell receptor (TCR), T104, for the KRAS.G12V mutation, a prevalent neoantigen in colorectal, lun...
ORGANISM(S): Homo sapiens (Human)